Introduction: Implementation of smokefree laws is followed by drops in hospital admissions for cardiovascular diseases and asthma. The impact of smokefree laws on use of non-hospital medical services has not been assessed. The purpose of this study is to evaluate the impact of Uruguay's national 100% smokefree legislation on non-hospital emergency care visits, hospitalizations for bronchospasm, and bronchodilator use.
Introduction

E
vidence about the benefits of smokefree legislation 1 is increasing. Uruguay, the first Latin American country to implement a comprehensive smokefree national law as part of its nationwide tobacco control campaign, has banned smoking in indoor public places and workplaces since March 2006. 2 Hospitalizations for myocardial infarction decreased after Uruguay's smokefree law, 3, 4 consistent with other countries. 5 Adult smoking prevalence in Uruguay was 29.7% in men and 19.1% in women in 2011. 6 The 2008-2010 Global Adult Tobacco Survey found that 11.8% of adults in Uruguay were exposed to secondhand smoke (SHS) in the workplace, 4.4% in restaurants, and 6.9% in government buildings. 7 A 2012 meta-analysis found that smokefree laws were associated with a 26% decrease in hospitalizations for respiratory disease, with significant reductions in asthma and pulmonary infections but not for chronic obstructive pulmonary disease (COPD). 1, [8] [9] [10] [11] [12] The impact of Uruguay's national 100% smokefree policy on non-hospital emergency visits for bronchospasm, hospital admissions for bronchospasm, and the number of administered puffs of inhaled β2-agonists and anticholinergic agents was evaluated. We hypothesized that visits for bronchospasm and bronchodilator administration would decrease after the law was enacted.
Methods
Study Design
Interrupted time series analysis evaluated the number of visits for bronchospasm from the Servicio de Urgencia, Asistencia y Traslado (SUAT, Emergency, Assistance and Move Service) nonhospital emergency medical service serving approximately 180,000 people in Montevideo, Uruguay. SUAT provides medical assistance outside of the hospital (e.g., at home, outpatient clinic, or public location). Most hospitalizations in Montevideo occur through such services.
A doctor and nurse are present at each emergency visit. The protocol followed for bronchospasm appears in Appendix Table 1 ; patients with incomplete or no response to treatment of moderate and severe exacerbations are accompanied to the hospital. At each visit, the physician documents the patient's diagnosis and disposition (e.g., hospital or home) in the electronic medical record using a cellular telephone. After each visit, the physician writes a handwritten note, and the nurse documents the names and doses of administered medications. These forms are later transcribed into the electronic medical record by the Department of Medical Informatics of SUAT Medical Emergency Service. For discrepancies between the diagnosis code entered via telephone and on the physician's note, the latter is used.
The 100% national smokefree law was implemented on 
Data Collection
De-identified data were retrieved from the electronic medical record by the chief of medical informatics of SUAT Medical Emergency Service, including date of visit, diagnosis code, total puffs of inhaled bronchodilators, and disposition. The investigators were provided with aggregate monthly statistics and had no access to individual patient-level data.
Study Population
Participants were individuals aged Z15 years with a non-hospital emergency visit for bronchospasm, defined as both (1) a diagnosis of asthma (ICD-10 J45) or COPD (ICD-10 J44) and (2) requiring inhaled β2-agonists during emergency care. As a retrospective review of medical records was performed, only patients meeting these two criteria were included.
Measures
The primary outcome was the number of monthly visits for bronchospasm from the non-hospital emergency service. Secondary outcomes included the number of individuals subsequently hospitalized and total and average (per patient treated) puffs of salbutamol (100 μg/puff), a short-acting β2-agonist, and ipratropium (20 μg/puff), a short-acting anticholinergic agent, administered by metered dose inhaler per patient per month in the nonhospital emergency setting and, when applicable, during transfer to the hospital.
Statistical Analysis
Negative binomial regression assessed changes in non-hospital emergency visits for bronchospasm after the smokefree law, with a dummy variable set to 0 before the law and 1 afterwards. Time was included to control for secular trends, and dummy variables for calendar month controlled for seasonal variations. Multiple linear regression assessed changes in amounts of inhaled medications using the same independent variables. No serial correlation was seen in residuals using the Durbin-Watson statistic (d¼1.7). Stata, version 13, was used for all analyses.
Results
The incidence of monthly non-hospital emergency visits for bronchospasm decreased by 15% after the law ( Table 1 ). The fitted values for non-hospital emergency visits were lower for the model including the smokefree law compared to a model containing the counterfactual of no law, obtained by setting the value for the dummy variable "smokefree law" to zero in the regression equation (Figure 1 ). There was no change in hospitalizations for bronchospasm (Table 1 ). (The minimum detectable effect was seven hospitalizations with 0.80 power based on 337 and 533 total hospitalizations before and after the smokefree law, respectively, with a standard deviation of 30 hospitalizations.) Total monthly puffs and average puffs per patient of salbutamol and ipratropium administered in the nonhospital emergency setting decreased (Table 1) . Total yearly events and administered medications are shown in Appendix Table 2 .
Discussion
Uruguay's national 100% smokefree law was followed by a 15% reduction in monthly non-hospital emergency visits for bronchospasm. These visits are typically the first interaction between patients having acute exacerbations of asthma or COPD and healthcare providers in Uruguay; after the smokefree law, there were fewer episodes requiring this immediate medical attention. Reduced emergency department visits for asthma have been seen after smokefree legislation in Kentucky. 13 Smokefree policies improve symptoms of respiratory and sensory irritation 14, 15 and spirometry parameters 16 in hospitality workers. Smokefree workplaces are associated with voluntary home smokefree policies, including in Uruguay, 17, 18 and also may encourage smoking cessation 19 and enhance cessation success among smokers. 20 This is particularly important for decreasing home SHS exposure and respiratory symptoms for susceptible individuals.
Uruguay's tobacco control program, which also included tobacco tax increases, restrictions on tobacco advertising, educational campaigns, graphic cigarette warning labels, and a ban on misleading tobacco packaging, was associated with a 4.3% decrease per year in per-person cigarette consumption and a 3.3% decrease in current tobacco use from 2005 to 2011. 21, 22 Decreased SHS exposure in workplaces and public places were also seen after Uruguay's smokefree law. 23 The lack of change in hospitalizations for bronchospasm after the smokefree law may be because milder exacerbations were primarily affected or because bronchospasm was unrelated to SHS exposure. As bronchospasm from asthma and COPD were evaluated together, direct comparison to past studies on asthma hospitalizations is not possible. Studies on smokefree laws and COPD hospitalizations have had varied findings, with one study 11 showing no significant difference and two 24, 25 showing reduced hospitalizations.
Limitations
This study has several limitations. Bronchospasm among both smokers and nonsmokers was included, and ageadjusted data were not available. Medication requirements for bronchospasm may be underestimated, as patients may have used inhalers prior to care. As above, Uruguay implemented multiple tobacco control measures during the time of this study, but given substantial overlap in dates of implementation, these could not all be controlled for. Finally, a comparison city was not used, and because these data were collected from one emergency service in one city, generalizability to other cities is unknown.
Conclusions
The drop in non-hospital emergency visits for bronchospasm following Uruguay's 100% smokefree law adds to the growing body of evidence supporting the health benefits of such policies. Replication of Uruguay's successful policy in other low-and middle-income countries can help reduce the burden of disease and costs associated with smoking worldwide. 
